EN
DISCOVERY OF NOVEL HCV NS5B POLYMERASE INHIBITORS BY IN SILICO APPROACHES
Abstract
Hepatitis C Virus (HCV) is a blood-borne RNA virus that causes inflammation of the liver that can lead to liver cirrhosis and hepatocellular carcinoma [1]. Non-structural protein 5B (NS5B) is an essential component of HCV for viral transcription and genome replication [2]. As there is no close mammalian analog for this enzyme, it has been the focus of many drug discovery projects [3]. In the present work, a combination of different computer-aided drug design approaches such as ensemble docking, binding free energy calculations, and quantitative structure-activity relationship (QSAR) model generation was applied to identify novel inhibitors of NS5B. In the first step, all available protein structures in Protein Data Bank in a complex with thumb site 2 inhibitors were collected. Then, an automated KNIME [4] workflow was generated to select a few representative structures of the conformational changes in the binding pocket upon ligand binding. In total eight NS5B-inhibitor complexes were selected for further in silico work. Next, a virtual combinatorial library was obtained using the privileged substructures of known NS5B inhibitors. Different congeneric series of compounds including phenylalanine derivatives, thiophene-2-carboxylic acid derivatives, and anthranilic acid derivatives were used for the database formation. Upon ligand preparation, over 182.000 molecules were built. Consequently, known thumb site 2 inhibitors were docked with GLIDE-SP [5-7] and rescored with Prime MM-GBSA [8,9] protocol implemented in Schrödinger software to estimate the docking and binding free energy scores that will be used as a threshold for filtering the newly produced combinatorial library. In addition, categorical and numerical QSAR models were generated based on the known thumb site 2 inhibitors and used in the post-filtering step. Compounds that were predicted as actives will be visually analyzed and selected further for synthesis and biological evaluation.
Keywords
References
- [1] Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359-362. [CrossRef]
- [2] Li HC, Yang CH, Lo SY. Cellular factors involved in the hepatitis C virus life cycle. World J Gastroenterol. 2021;27(28):4555-4581. [CrossRef]
- [3] Powdrill MH, Bernatchez JA, Götte M. Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B. Viruses. 2010;2(10):2169-2195. [CrossRef]
- [4] Roughley SD. Five Years of the KNIME Vernalis Cheminformatics Community Contribution. Curr Med Chem. 2020;27(38):6495-6522. [CrossRef]
- [5] Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739-1749. [CrossRef]
- [6] Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47(7):1750-1759. [CrossRef]
- [7] Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra Precision Glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes. J Med Chem. 2006;49(21):6177-6196. [CrossRef]
- [8] Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesner RA. A hierarchical approach to all-atom protein loop prediction. Proteins. 2004;55(2):351-367. [CrossRef]
Details
Primary Language
English
Subjects
Pharmacology and Pharmaceutical Sciences (Other)
Journal Section
Conference Paper
Authors
Publication Date
June 28, 2025
Submission Date
January 24, 2023
Acceptance Date
January 25, 2023
Published in Issue
Year 2023 Volume: 27 Number: Current Research Topics In Pharmacy: In silico Approaches for Drug Design and Discovery
APA
Karaman Mayack, B. (2025). DISCOVERY OF NOVEL HCV NS5B POLYMERASE INHIBITORS BY IN SILICO APPROACHES. Journal of Research in Pharmacy, 27(Current Research Topics In Pharmacy: In silico Approaches for Drug Design and Discovery), 13-15. https://doi.org/10.29228/jrp.456
AMA
1.Karaman Mayack B. DISCOVERY OF NOVEL HCV NS5B POLYMERASE INHIBITORS BY IN SILICO APPROACHES. J. Res. Pharm. 2025;27(Current Research Topics In Pharmacy: In silico Approaches for Drug Design and Discovery):13-15. doi:10.29228/jrp.456
Chicago
Karaman Mayack, Berin. 2025. “DISCOVERY OF NOVEL HCV NS5B POLYMERASE INHIBITORS BY IN SILICO APPROACHES”. Journal of Research in Pharmacy 27 (Current Research Topics In Pharmacy: In silico Approaches for Drug Design and Discovery): 13-15. https://doi.org/10.29228/jrp.456.
EndNote
Karaman Mayack B (July 1, 2025) DISCOVERY OF NOVEL HCV NS5B POLYMERASE INHIBITORS BY IN SILICO APPROACHES. Journal of Research in Pharmacy 27 Current Research Topics In Pharmacy: In silico Approaches for Drug Design and Discovery 13–15.
IEEE
[1]B. Karaman Mayack, “DISCOVERY OF NOVEL HCV NS5B POLYMERASE INHIBITORS BY IN SILICO APPROACHES”, J. Res. Pharm., vol. 27, no. Current Research Topics In Pharmacy: In silico Approaches for Drug Design and Discovery, pp. 13–15, July 2025, doi: 10.29228/jrp.456.
ISNAD
Karaman Mayack, Berin. “DISCOVERY OF NOVEL HCV NS5B POLYMERASE INHIBITORS BY IN SILICO APPROACHES”. Journal of Research in Pharmacy 27/Current Research Topics In Pharmacy: In silico Approaches for Drug Design and Discovery (July 1, 2025): 13-15. https://doi.org/10.29228/jrp.456.
JAMA
1.Karaman Mayack B. DISCOVERY OF NOVEL HCV NS5B POLYMERASE INHIBITORS BY IN SILICO APPROACHES. J. Res. Pharm. 2025;27:13–15.
MLA
Karaman Mayack, Berin. “DISCOVERY OF NOVEL HCV NS5B POLYMERASE INHIBITORS BY IN SILICO APPROACHES”. Journal of Research in Pharmacy, vol. 27, no. Current Research Topics In Pharmacy: In silico Approaches for Drug Design and Discovery, July 2025, pp. 13-15, doi:10.29228/jrp.456.
Vancouver
1.Berin Karaman Mayack. DISCOVERY OF NOVEL HCV NS5B POLYMERASE INHIBITORS BY IN SILICO APPROACHES. J. Res. Pharm. 2025 Jul. 1;27(Current Research Topics In Pharmacy: In silico Approaches for Drug Design and Discovery):13-5. doi:10.29228/jrp.456